Time to Next Treatment in Patients with Chronic Lymphocytic Leukemia Initiating First-Line Ibrutinib or Acalabrutinib

References

• Siegel RL , Miller KD , Jemal A . Cancer statistics, 2020. CA Cancer J. Clin. 70(1), 7–30 (2020).
   PubMed Web of Science ®Google Scholar
• National Cancer Institute Surveillance Epidemiology and End Results Program . Cancer Stat Facts: Leukemia — Chronic Lymphocytic Leukemia (CLL). (2022).
   Google Scholar
• Hallek M . Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am. J. Hematol. 94(11), 1266–1287 (2019).
   PubMed Web of Science ®Google Scholar
• GAZYVA (obinutuzumab) . Prescribing Information. Genentech, Inc, South San Francisco, CA (2022).
   Google Scholar
• RITUXAN (rituximab) . Prescribing Information. Genentech, Inc, South San Francisco, CA (2021).
   Google Scholar
• Delgado J , Nadeu F , Colomer D , Campo E . Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies. Haematologica 105(9), 2205–2217 (2020).
   PubMed Web of Science ®Google Scholar
• VENCLEXTA (venetoclax) . Prescribing Information. Genentech, Inc, South San Francisco, CA (2022).
   Google Scholar
• ZYDELIG® (idelalisib) . Prescribing Information. Gilead Sciences, Inc, Foster City, CA (2014).
   Google Scholar
• COPIKTRA (duvelisib) . Prescribing Information. Verastem, Inc, Needham, MA (2018).
   Google Scholar
• IMBRUVICA (ibrutinib) . Prescribing Information. Janssen Biotech, Inc, Horsham, PA (2022).
   Google Scholar
• CALQUENCE (acalabrutinib) . Prescribing Information. AstraZeneca Pharmaceuticals LP, Wilmington, DE (2022).
   Google Scholar
• BRUKINSA (zanubrutinib) . Prescribing Information. BeiGene, Ltd, San Mateo, CA (2023).
   Google Scholar
• Patel K , Pagel JM . Current and future treatment strategies in chronic lymphocytic leukemia. J Hematol Oncol 14(1), 1–20 (2021).
   PubMed Web of Science ®Google Scholar
• Burger JA , Tedeschi A , Barr PM et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N. Engl. J. Med. 373(25), 2425–2437 (2015).
   PubMed Web of Science ®Google Scholar
• Byrd JC , Brown JR , O’Brien S et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N. Engl. J. Med. 371(3), 213–223 (2014).
   PubMed Web of Science ®Google Scholar
• Fraser G , Cramer P , Demirkan F et al. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia 33(4), 969–980 (2019).
   PubMed Web of Science ®Google Scholar
• Moreno C , Greil R , Demirkan F et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20(1), 43–56 (2019).
   PubMed Web of Science ®Google Scholar
• Shanafelt TD , Wang XV , Kay NE et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N. Engl. J. Med. 381(5), 432–443 (2019).
   PubMed Web of Science ®Google Scholar
• Woyach JA , Ruppert AS , Heerema NA et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N. Engl. J. Med. 379(26), 2517–2528 (2018).
   PubMed Web of Science ®Google Scholar
• Shanafelt TD , Wang XV , Hanson CA et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood 140(2), 112–120 (2022).
   PubMed Web of Science ®Google Scholar
• Munir T , Brown JR , O’Brien S et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am. J. Hematol. 94(12), 1353–1363 (2019).
   PubMed Web of Science ®Google Scholar
• Barr PM , Owen C , Robak T et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv 6(11), 3440–3450 (2022).
   PubMed Web of Science ®Google Scholar
• Byrd JC , Furman RR , Coutre SE et al. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. Clin Cancer Res 26(15), 3918–3927 (2020).
   PubMed Web of Science ®Google Scholar
• Moreno C , Greil R , Demirkan F et al. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. Haematologica 107(9), 2108–2120 (2022).
   PubMed Web of Science ®Google Scholar
• Fraser GAM , Chanan-Khan A , Demirkan F et al. Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk. Lymphoma 61(13), 3188–3197 (2020).
   PubMed Web of Science ®Google Scholar
• Woyach JA , Ruppert AS , Heerema NA et al. Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy. Blood 138(Suppl. 1), 639–639 (2021).
   Google Scholar
• Sharman JP , Egyed M , Jurczak W et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet 395(10232), 1278–1291 (2020).
   PubMed Web of Science ®Google Scholar
• Burger JA , Barr PM , Robak T et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia 34(3), 787–798 (2020).
   PubMed Web of Science ®Google Scholar
• Brown JR , Eichhorst B , Hillmen P et al. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. N. Engl. J. Med. 388(4), 319–332 (2022).
   PubMed Web of Science ®Google Scholar
• Byrd JC , Hillmen P , Ghia P et al. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. J. Clin. Oncol. 39(31), 3441–3452 (2021).
   PubMed Web of Science ®Google Scholar
• Hallek M , Cheson BD , Catovsky D et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131(25), 2745–2760 (2018).
   PubMed Web of Science ®Google Scholar
• Hanel W , Briski R , Ross CW et al. A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome. Am. J. Hematol. 91(12), E491–E495 (2016).
   PubMed Web of Science ®Google Scholar
• Bruno AS , Willson JL , Opalinska JM et al. Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma. Expert Rev Hematol 13(9), 1017–1025 (2020).
   PubMed Web of Science ®Google Scholar
• Martin P , Cohen JB , Wang M et al. Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts. J. Clin. Oncol. 41(3), 541–554 (2022).
   PubMed Web of Science ®Google Scholar
• Atrash S , Flahavan EM , Xu T et al. Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis. Blood Cancer J 12(3), 1–11 (2022).
   PubMed Web of Science ®Google Scholar
• Cowey CL , Liu FX , Boyd M , Aguilar KM , Krepler C . Real-world treatment patterns and clinical outcomes among patients with advanced melanoma: a retrospective, community oncology-based cohort study (A STROBE-compliant article). Medicine (Baltimore) 98(28), 1–12 (2019).
   Web of Science ®Google Scholar
• Chen CC , Parikh K , Abouzaid S et al. Real-World Treatment Patterns, Time to Next Treatment, and Economic Outcomes in Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide or Carfilzomib. J Manag Care Spec Pharm 23(2), 236–246 (2017).
   PubMed Web of Science ®Google Scholar
• Huang Q , Deering KL , Harshaw Q , Leslie LA . Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status. Adv Ther 39(7), 3292–3307 (2022).
   PubMed Web of Science ®Google Scholar
• Narezkina A , Akhter N , Lu X et al. Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke. Clin Lymphoma Myeloma Leuk 22(11), e959–e971 (2022).
   PubMed Web of Science ®Google Scholar
• Emond B , Sundaram M , Romdhani H , Lefebvre P , Wang S , Mato A . Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy. Clin Lymphoma Myeloma Leuk 19(12), 763–775.e762 (2019).
   PubMed Web of Science ®Google Scholar
• Campbell BA , Scarisbrick JJ , Kim YH , Wilcox RA , McCormack C , Prince HM . Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma. Cancers (Basel) 12(8), 1–11 (2020).
   Web of Science ®Google Scholar
• Rivera DR , Henk HJ , Garrett-Mayer E et al. The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies. Clin. Pharm. Therap. 111(1), 283–292 (2022).
   PubMed Web of Science ®Google Scholar
• Li Q , Zhang H , Chen Z et al. Validation of Real-World Data-based Endpoint Measures of Cancer Treatment Outcomes. AMIA Annu Symp Proc 2021, 716–725 (2021).
   PubMedGoogle Scholar
• Stilgenbauer S , Furman RR , Zent CS . Management of chronic lymphocytic leukemia. Am Soc Clin Oncol Educ Book 35(1), 164–175 (2015).
   Google Scholar
• Lee P , Kistler KD , Douyon L et al. Systematic Literature Review of Real-World Effectiveness Results Data for First-Line Ibrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. Drugs - Real World Outcomes 10(1), 11–22(2022).
   PubMedGoogle Scholar
• Huang Q , Emond B , Lafeuille M-H et al. Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia. Curr. Med. Res. Opin. 36(12), 2009–2018 (2020).
   PubMed Web of Science ®Google Scholar
• Kabadi SM , Goyal RK , Nagar SP , Kaye JA , Davis KL . Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States. Cancer Med. 8(8), 3803–3810 (2019).
   PubMed Web of Science ®Google Scholar
• Hallek M , Al-Sawaf O . Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am. J. Hematol. 96(12), 1679–1705 (2021).
   PubMed Web of Science ®Google Scholar
• Munoz J , Sarosiek S , Castillo JJ . Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies. Oncologist 28(4), 309–318 (2023).
   PubMedGoogle Scholar
• O’Brien SM , Brown JR , Byrd JC et al. Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice. Front Oncol 11, 720704 (2021).
   PubMed Web of Science ®Google Scholar
• Stephens DM , Byrd JC . How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood 133(12), 1298–1307 (2019).
   PubMed Web of Science ®Google Scholar
• Davids M , Mato A , Hum J et al. Majic: A Phase 3 Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. Blood 138(Suppl. 1), 1553–1554 (2021).
   Google Scholar
• Davids M , Lampson B , Tyekucheva S et al. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. Lancet Oncol 22(10), 1391–1402 (2021).
   PubMed Web of Science ®Google Scholar
• Jain N , Keating M , Thompson P et al. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N. Engl. J. Med. 380(22), 2095–2103 (2019).
   PubMed Web of Science ®Google Scholar
• Lu X , Emond B , Morrison L et al. P-041 Real-world Comparison of Adherence Between Patients with Chronic Lymphocytic Leukemia Treated with Single-agent Ibrutinib or Acalabrutinib In First Line. Am. J. Hematol. 97(S3), S26–S26 (2022).
   PubMedGoogle Scholar
• Lu X , Emond B , Qureshi Z et al. CLL-492 Real-World Adherence to First-Line Ibrutinib and Acalabrutinib Single-Agent Among Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Lymphoma Myeloma and Leukemia 22, S280–S281 (2022).
   Web of Science ®Google Scholar
• Coleman CI , Limone B , Sobieraj DM et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm 18(7), 527–539 (2012).
   PubMed Web of Science ®Google Scholar
• Barr PM , Brown JR , Hillmen P et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood 129(19), 2612–2615 (2017).
   PubMed Web of Science ®Google Scholar
• Fernandez-Lazaro CI , Garcia-Gonzalez JM , Adams DP et al. Adherence to treatment and related factors among patients with chronic conditions in primary care: a cross-sectional study. BMC Fam Pract 20(1), 132 (2019).
   PubMed Web of Science ®Google Scholar
• Gillespie CW , Morin PE , Tucker JM , Purvis L . Medication Adherence, Health Care Utilization, and Spending Among Privately Insured Adults With Chronic Conditions in the United States, 2010–2016. Am. J. Med. 133(6), 690–704 e619 (2020).
   PubMed Web of Science ®Google Scholar
• Ibrahim AR , Eliasson L , Apperley JF et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 117(14), 3733–3736 (2011).
   PubMed Web of Science ®Google Scholar
• Santoleri F , Sorice P , Lasala R , Rizzo RC , Costantini A . Patient adherence and persistence with Imatinib, Nilotinib, Dasatinib in clinical practice. PLOS One 8(2), e56813 (2013).
   PubMed Web of Science ®Google Scholar
• Bhat SA , Gambril J , Azali L et al. Ventricular arrhythmias and sudden death events following acalabrutinib initiation. Blood 140(20), 2142–2145 (2022).
   PubMed Web of Science ®Google Scholar
• Blombery P , Thompson ER , Lew TE et al. Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance. Blood Adv 6(20), 5589–5592 (2022).
   PubMed Web of Science ®Google Scholar
• Ferrajoli A , Byrd JC , Ghia P et al. CLL-354: Pooled Analysis of Cardiovascular Events from Clinical Trials Evaluating Acalabrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia (CLL). Clinical Lymphoma Myeloma and Leukemia 21, S323 (2021).
   Web of Science ®Google Scholar
• Kumar PS , Wiczer T , Rosen L et al. Evaluation of the Incidence and Risk Factors Associated with Bleeding Events in Patients Receiving Acalabrutinib Therapy. Blood 138, 3729 (2021).
   Web of Science ®Google Scholar
• Sharman J , Egyed M , Jurczak W , Skarbnik A , Pagel J , Flinn I . Acalabrutinib + Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: ELEVATE-TN 4-Year Follow-up. In: American Society for Clinical Oncology (ASCO) Annual Meeting. (2021).
   Google Scholar
• Jacobs R , Wang R , He J et al. Real World Treatment Patterns in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Switching from First Line Ibrutinib to Acalabrutinib. Blood 140(S1), 8017–8018 (2022).
   Google Scholar
• Cull G , Burger JA , Opat S et al. Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study. Br. J. Haematol. 196(5), 1209–1218 (2022).
   PubMed Web of Science ®Google Scholar
• Brown JR . LBA-6 Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study. 64th Annual Americal Society of Hematology Annual Meeting and Exposition (2022).
   Google Scholar
• Jones JA , Mato AR , Wierda WG et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. The Lancet Oncology 19(1), 65–75 (2018).
   PubMed Web of Science ®Google Scholar
• Molica S , Giannarelli D , Montserrat E . Minimal Residual Disease and Survival Outcomes in Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis. Clinical Lymphoma Myeloma Leukemia 19(7), 423–430 (2019).
   PubMed Web of Science ®Google Scholar
• Mato AR , Barrientos JC , Ghosh N et al. Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry. Clinical Lymphoma Myeloma Leukemia 20(3), 174–183 e173 (2020).
   PubMed Web of Science ®Google Scholar
• Quan H , Li B , Couris CM et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am. J. Epidemiol. 173(6), 676–682 (2011).
   PubMed Web of Science ®Google Scholar